ArticleCNS oncology2017
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
Article in CNS oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Molecular features in gangliogliomas: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Anaplastic pleomorphic xanthoastrocytoma with leptomeningeal dissemination presenting with cranial neuropathy in an adult patient: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging.BMC cancer · 2024Article
- Clinical features and surgical outcomes of high grade pleomorphic xanthoastrocytomas: a single-center experience with a systematic review.Frontiers in oncology · 2023Article
- The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- Differences in treatment patterns and overall survival between grade II and anaplastic pleomorphic xanthoastrocytomas.Journal of neuro-oncology · 2021Article
- Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors.Paediatric drugs · 2020Review
- Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report.BMC neurology · 2020Article
- Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.Neuro-oncology · 2019Article
- Pleomorphic xanthoastrocytoma: a brief review.CNS oncology · 2019Review
- Efficacy of Dabrafenib for three children with brainstem BRAFJournal of neuro-oncology · 2019Article
- Demography, Pattern of Care, and Survival in Patients with Xanthoastrocytoma: A Systematic Review and Individual Patient Data Analysis of 325 Cases.Journal of neurosciences in rural practice · 2019Article
- Uncommon low-grade brain tumors.Neuro-oncology · 2019Review
- BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.CNS oncology · 2018Article
- Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.Journal of neuro-oncology · 2018Article
- Dabrafenib and trametinib in BRAFV600E mutated glioma.CNS oncology · 2017Article
- Neuro-Oncology: Current Concepts and Emerging Therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Article
- A case series of pediatric survivors of anaplastic pleomorphic xanthoastrocytoma.Neuro-oncology advancesArticle
- Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor. Anaplastic features are found in 20-30% of cases of PXA and are associated with poor outcomes. Typical treatment is with gross total resection, followed by radiation therapy and cytotoxic chemotherapy at relapse. BRAFV600 mutations have been identified in 38-60% of patients with PXA. Several case reports and small case series have identified clinical benefit with BRAF inhibition in patients with BRAFV600-mutated PXA. We report the second published case of successful treatment with the BRAF inhibitor dabrafenib in a female patient with relapsed anaplastic PXA with a BRAFV600 mutation, and the first published case of dabrafinib treatment following intolerance to vemurafenib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.